Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 15/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.47 |
| ▸ | PPARG | P37231 | 5/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405198 | 0.88 | NR1H2 (0.51) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL6099041 | 0.86 | NR1H2 (0.65) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL6405303 | 0.85 | NR1H2 (0.65) | NR1H2NR1H3 | |
| SCHEMBL6405323 | 0.83 | NR1H2 (0.55) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL6405584 | 0.81 | NR1H2 (0.54) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL6406343 | 0.81 | NR1H2 (0.54) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL6405163 | 0.81 | NR1H2 (0.50) | NR1H2NR1H3 | |
| SCHEMBL6405155 | 0.80 | NR1H2 (0.52) | NR1H2NR1H3PPARGPPARDPPARA | |
| SCHEMBL6406547 | 0.79 | NR1H2 (0.59) | NR1H2NR1H3PPARA | |
| SCHEMBL6405354 | 0.79 | NR1H2 (0.72) | NR1H2NR1H3PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534696-A1 | THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004011448-A1 | THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS | MERCK & CO., INC. (US) | 2004-02-05 | — | — | WO | disclosed |